-
2 weeks ago | 
ca.marketscreener.com | Kamal Choudhury |Puyaan Singh
Published on 2025-05-21 at 05:19, updated on 2025-05-21 at 08:07 (Reuters) -Medical device maker Medtronic said on Wednesday it plans to separate its diabetes business, which houses its insulin pumps and other wearable devices, into a stand-alone company and forecast 2026 adjusted profit below estimates. The unit has been struggling over the last few years following regulatory concerns over quality management and cybersecurity issues related to its certain devices.
-
2 weeks ago | 
marketscreener.com | Kamal Choudhury |Puyaan Singh
Published on 05/21/2025 at 05:19, updated on 05/21/2025 at 12:39 (Reuters) -Medical device maker Medtronic said on Wednesday it plans to separate its diabetes business, which houses its insulin pumps and other wearable devices, into a stand-alone company and forecast 2026 adjusted profit below estimates. The unit has been struggling over the last few years following regulatory concerns over quality management and cybersecurity issues related to its certain devices.
-
2 weeks ago | 
today.westlaw.com | Puyaan Singh |Sriparna Roy |Nivedita Bhattacharjee |Kamal Choudhury
(Reuters) -Medical device maker Medtronic said on Wednesday it plans to separate its diabetes business, which houses its insulin pumps and other wearable devices, into a stand-alone company and forecast 2026 adjusted profit below estimates.
-
1 month ago | 
today.westlaw.com | Kamal Choudhury |Shailesh Kuber
(Reuters) - Zimmer Biomet Holdings on Monday lowered its 2025 adjusted profit forecast, and said it expects the proposed trade tariffs to weigh on the company's earnings this year. The Warsaw, Indiana-based company's shares fell 10% to $92 in morning...
-
1 month ago | 
azdailysun.com | Sneha K |Kamal Choudhury
By Sneha S K and Kamal Choudhury(Reuters) -The U.S. Food and Drug Administration approved Abeona Therapeutics' gene therapy for a rare skin disorder on Tuesday.
-
1 month ago | 
kfgo.com | Sneha K |Kamal Choudhury
By Sneha S K and Kamal Choudhury(Reuters) -The U.S. Food and Drug Administration approved Abeona Therapeutics’ gene therapy for a rare skin disorder on Tuesday. Shares of the Cleveland-based drugmaker rose 13% in premarket trading. The gene therapy, called Zevaskyn, is approved to treat adult and pediatric patients with recessive dystrophic epidermolysis bullosa.
-
1 month ago | 
kelo.com | Sneha K |Kamal Choudhury
By Sneha S K and Kamal Choudhury(Reuters) -The U.S. Food and Drug Administration approved Abeona Therapeutics’ gene therapy for a rare skin disorder on Tuesday. Shares of the Cleveland-based drugmaker rose 13% in premarket trading. The gene therapy, called Zevaskyn, is approved to treat adult and pediatric patients with recessive dystrophic epidermolysis bullosa.
-
1 month ago | 
conexiant.com | Kamal Choudhury |Sneha K
The U.S. Food and Drug Administration approved Abeona Therapeutics' cell-based gene therapy, pz-cel (Zevaskyn), for recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn is approved for the treatment of adult and pediatric patients with RDEB. Patients with RDEB have markedly fragile skin, with recurrent blistering and chronic, nonhealing wounds.
-
1 month ago | 
today.westlaw.com | Patrick Wingrove |Mohammed Shamsi |Savyata Mishra |Kamal Choudhury
(Reuters) -U.S. Food and Drug Administration Commissioner Martin Makary announced on Thursday a policy to limit employees of companies regulated by the agency, such as pharmaceutical firms, from serving as official members on FDA's advisory...
-
2 months ago | 
sightmagazine.com.au | Mariam Sunny |Kamal Choudhury |David Adams
ReutersTuberculosis (TB) infections among children in the European region rose 10 per cent in 2023, indicating ongoing transmission and the need for immediate public health measures to control the spread, the World Health Organization said on Monday. WHO’s European region, which comprises 53 countries in Europe and Central Asia, reported more than 7,500 cases among children under 15 years of age in 2023, an increase of over 650 cases compared to 2022.
